{
  "id": 227045,
  "title": "Moderna's mRNA flu shot earns FDA approval after rollercoaster review",
  "url": "https://urgent.news/2026/08/06/modernas-mrna-flu-shot-earns-fda-approval-after-rollercoaster-review",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-06T16:31:06.000Z",
  "source": {
    "name": "Ars Technica Health",
    "slug": "ars-technica-health",
    "url": "https://arstechnica.com/health/2026/08/modernas-mrna-flu-shot-earns-fda-approval-after-rollercoaster-review/"
  },
  "original_language": "en",
  "account": "Moderna's groundbreaking mRNA flu vaccine, known as mFLUSIVA, has finally received approval from the Food and Drug Administration (FDA) after a tumultuous review process. This achievement marks the first instance of an mRNA-based flu shot receiving FDA approval in the United States. The vaccine, designed for adults aged 50 and above, was approved following a unanimous vote by FDA advisors in June. This decision was grounded in the vaccine's superior efficacy compared to traditional flu shots, coupled with a strong safety record demonstrated through extensive trials involving nearly 44,000 participants. The FDA had initially set a target date of August 5 for a final decision on the vaccine's approval. While the FDA advisors' unanimous support initially looked promising for Moderna's vaccine, the journey to approval was far from straightforward. Health Secretary Robert F. Kennedy Jr., a vocal anti-vaccine advocate who has made it his mission to undermine vaccination efforts during his tenure, introduced several obstacles along the way. A prime example was his swift cancellation of a federal campaign promoting flu shots during a particularly harsh flu season. Despite the CDC having already funded this campaign, Kennedy's decision came at a time when the disease was claiming a significant number of young lives.",
  "summary": "Moderna's new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.",
  "key_points": [
    "Moderna's mRNA flu vaccine, mFLUSIVA, receives FDA approval.",
    "Vaccine approved for adults 50+, following unanimous FDA vote.",
    "FDA initially set approval date for August 5, but faced obstacles."
  ],
  "editors_take": "The FDA approval of Moderna's mRNA flu shot sets a new precedent for vaccine technology and may shift the flu vaccine market, giving Moderna a foothold with its innovative approach.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Ars Technica",
        "title": "Moderna's mRNA flu shot earns FDA approval after rollercoaster review",
        "url": "https://urgent.news/2026/08/06/modernas-mrna-flu-shot-earns-fda-approval-after-rollercoaster-review-230316",
        "published": "2026-08-06T16:31:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}